See the DrugPatentWatch profile for Tysabri
When does the Tysabri (natalizumab) patent expire?
Publicly available information on a specific “Tysabri patent expiry” date can be tricky because natalizumab has multiple patents tied to different countries, formulations, and use claims. Your search phrase “greyb” likely points to “grey area” or “grey market” concerns, but the key fact is that Tysabri’s market exclusivity/patent protection timeline depends on jurisdiction and which patent or exclusivity mechanism you’re referring to (primary composition-of-matter vs. later-use or process patents).
If you tell me the country/region (US, EU, UK, Canada, etc.), I can narrow to the relevant exclusivity window based on what’s typically tracked there.
Is there a “grey” period where biosimilars or copies can launch?
The “grey” concept around biologics usually comes from how regulators and courts handle:
- patent protection for the reference biologic,
- additional patents that cover specific indications, dosing, manufacturing steps, or formulations,
- regulatory exclusivity rules that can delay approval even if patent coverage is challenged.
For natalizumab specifically, biosimilar entry timing will depend on whether any biosimilar applicants can overcome (or work around) the relevant patents and how exclusivity is applied in that jurisdiction. Those timelines can produce a window where approvals are delayed or litigation is still ongoing, which is often what people mean by “grey.”
What actually controls entry for biosimilars after Tysabri?
Two things tend to gate market entry:
1. Regulatory approval (biosimilar or follow-on development pathway).
2. Legal barriers (patent claims and injunctions or settlement timelines).
Even when a biosimilar is approved, sales can still be blocked in practice if patents are enforced or if an injunction is in place.
How can I verify the exact expiry date you mean?
To pinpoint “Tysabri patent expiry” you need three details:
- Jurisdiction (US vs EU vs UK, etc.).
- Which right you mean (patent vs data exclusivity vs market exclusivity).
- Which claim type (composition, method of treatment, formulation, manufacturing).
If you share the jurisdiction you care about and whether you mean “patent” or “exclusivity,” I can help you map what to look for and how it’s usually described (including how to interpret “expiry” vs “expiration” vs “last day of protection”).
Does patent expiry automatically mean cheaper alternatives appear immediately?
No. Even after patents or exclusivity expire, there can be delays due to:
- ongoing litigation resolution,
- launch timing decisions by biosimilar makers,
- payer formulary and contracting cycles,
- manufacturing scale-up.
Quick clarification (so I can answer precisely)
What does “greyb” mean in your question—are you asking about:
1) the exact patent expiry / exclusivity expiry date, or
2) the “grey area” for biosimilar launch and market timing?
Also, which country/region should I use?